Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Guggenheim

Biotechnology Fund Investor Class (RYOIX)

Ticker RYOIX · · Holdings as of Jun 30, 2026

Expense ratio
1.38%$138/yr per $10k
5-yr return
+4.0%annualized
1-yr return
+30.7%as of Dec 2025
Net assets
$136.8Mall share classes
Holdings
74

Bottom line

Is RYOIX a good fund? The bottom line

RYOIX is the Investor Class share class of Biotechnology Fund, a managed technology sector mutual fund from Guggenheim.

It charges 1.38% — about $138 a year on every $10,000 invested, more expensive than 82% of technology sector funds we track.

It returned +30.7% over one year, +4.0% a year over five years, +5.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $137 million in net assets and 74 holdings, its largest position is Abbvie Inc (8.2%) and the top 10 make up 36.2% of the portfolio.

The closest lower-cost alternative we found is IBBQ (0.19%, 58% top-holdings overlap).

What to watch

  • Expensive for its category (1.38%)

Updated Nov 19, 2026

What RYOIX invests in

The Biotechnology Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the biotechnology industry, including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services (Biotechnology Companies).

Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Biotechnology Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor. The Fund may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations.…

From the fund's prospectus (filed Jul 29, 2026).

RYOIX performance

Fund calendar-year total returns, 2016–2025 2016: −19.5%; 2017: +29.7%; 2018: −9.0%; 2019: +25.0%; 2020: +22.1%; 2021: +1.8%; 2022: −13.1%; 2023: +6.1%; 2024: −0.7%; 2025: +30.7% −20% 2016 +30% 2017 −9% 2018 +25% 2019 +22% 2020 +2% 2021 −13% 2022 +6% 2023 −1% 2024 +31% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RYOIX+30.7%+4.0%+5.9%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full RYOIX performance history →

What RYOIX costs

On a $10,000 investment, RYOIX's 1.38% expense ratio costs about $138 a year. The prospectus estimates $1,709 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full RYOIX fee table →

RYOIX top 10 holdings

#Holding% of fund
1Abbvie Inc ABBV8.17%
2Amgen Inc AMGN5.05%
3Gilead Sciences Inc GILD4.49%
4Vertex Pharmaceuticals Inc VRTX4.32%
5Regeneron Pharmaceuticals Inc REGN2.93%
6Revolution Medicines Inc RVMD2.48%
7Alnylam Pharmaceuticals Inc ALNY2.36%
8Beone Medicines Ltd ONC2.17%
9Moderna Inc MRNA2.15%
10Biogen Inc BIIB2.13%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 36.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to RYOIX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
InvescoIBBQ Invesco Nasdaq Biotechnology ETF0.19%58% Compare
iSharesIBB iShares Biotechnology ETF0.44%55% Compare
FidelityFBIOX Biotechnology Portfolio0.62%53% Compare

More funds like RYOIX →

RYOIX FAQ

What is the expense ratio of RYOIX?
RYOIX's expense ratio is 1.38%, which works out to about $138 a year for every $10,000 invested. The prospectus estimates total costs of $1,709 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RYOIX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.38%). This is general information, not personalized advice.
What does RYOIX hold?
RYOIX's largest holdings are Abbvie Inc (8.2%), Amgen Inc (5.0%), Gilead Sciences Inc (4.5%), Vertex Pharmaceuticals Inc (4.3%), Regeneron Pharmaceuticals Inc (2.9%). It holds 74 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RYOIX's 5-year return?
RYOIX returned +4.0% a year over the five years ending Dec 31, 2025, and +5.9% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to RYOIX?
IBBQ (Invesco Nasdaq Biotechnology ETF) overlaps about 58% with RYOIX and charges 0.19%.
Who manages RYOIX?
RYOIX is offered by Guggenheim through Rydex Series Funds.